Status:
RECRUITING
The Jinling Cohort
Lead Sponsor:
Nanjing Shihejiyin Technology, Inc.
Conditions:
Cancer
Multi Cancer Early Screening
Eligibility:
All Genders
45-75 years
Brief Summary
The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.
Detailed Description
Its aim is to assess the performance and clinical utility of the Multi-omics liquid biopsy MCED test MERCURY in an average risk Chinese population. Each participant will undergo peripheral blood colle...
Eligibility Criteria
Inclusion
- 1、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent
Exclusion
- Pregnant women;
- Individuals who have history of cancer or current diagnosis of cancer;
- Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;
- Individulas who have blood transfusion within 30 days prior to the blood draw;
- Individuals who have an acute infection or inflammation within 14 days prior to the blood draw;
- Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw;
- Individuals who will not be able to comply with the protocol procedures judged by researchers
Key Trial Info
Start Date :
June 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 15 2027
Estimated Enrollment :
15000 Patients enrolled
Trial Details
Trial ID
NCT06011694
Start Date
June 15 2022
End Date
May 15 2027
Last Update
August 25 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing Jiangbei People's Hospital
Nanjing, Jiangsu, China, 210000
2
The Fourth Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210000